Literature DB >> 22991959

Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT.

John B Christoforidis1, Michelle M Williams, Shankaran Kothandaraman, Krishan Kumar, Frank J Epitropoulos, Michael V Knopp.   

Abstract

PURPOSE: To determine the anatomic characteristics and pharmacokinetic properties of intravitreally-placed aflibercept in a rabbit model.
MATERIALS AND METHODS: Four Dutch-belted rabbits underwent intravitreal injection with I-124-aflibercept. Serial imaging with PET/CT imaging was performed on days 0, 2, 5, 7, 14, 21, 28 and 35. Measured radioactivity emission in becquerels/mL was used to calculate the half-lives for aflibercept.
RESULTS: I-124 aflibercept was confined within the vitreous cavity for the duration of the study. I-124 aflibercept could be detected in the vitreous cavity until day 28 and the average retention time with standard error after correction for radioactive decay was 4.58 ± 0.07 days.
CONCLUSIONS: I-124 aflibercept was only visible in the vitreous cavity by PET/CT imaging following intravitreal injection. The retention properties were found to be comparable to those measured by other reported methods.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22991959     DOI: 10.3109/02713683.2012.727521

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  17 in total

Review 1.  Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion.

Authors:  Sheridan M Hoy
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

Review 2.  Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

3.  Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.

Authors:  S J Park; J Oh; Y-K Kim; J H Park; J Y Park; H K Hong; K H Park; J-E Lee; H M Kim; J Y Chung; S J Woo
Journal:  Eye (Lond)       Date:  2015-01-16       Impact factor: 3.775

Review 4.  Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.

Authors:  Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy
Journal:  Front Med (Lausanne)       Date:  2022-06-06

5.  Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.

Authors:  Yoshitsugu Saishin; Yuka Ito; Masato Fujikawa; Tomoko Sawada; Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2016-09-22       Impact factor: 2.447

Review 6.  New radiotracers for imaging of vascular targets in angiogenesis-related diseases.

Authors:  Hao Hong; Feng Chen; Yin Zhang; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2014-07-30       Impact factor: 15.470

Review 7.  Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion.

Authors:  Lily P H Yang; Kate McKeage
Journal:  Drugs Aging       Date:  2014-05       Impact factor: 3.923

8.  Bimonthly injections of ranibizumab for age-related macular degeneration.

Authors:  Tomoko Sawada; Masashi Kakinoki; Xiying Wang; Hajime Kawamura; Yoshitsugu Saishin; Masahito Ohji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-05       Impact factor: 3.117

Review 9.  The role of aflibercept in the management of diabetic macular edema.

Authors:  Andrew A Chang; Thomas Hong; Shaun Y Ewe; Bobak Bahrami; Geoffrey K Broadhead
Journal:  Drug Des Devel Ther       Date:  2015-08-06       Impact factor: 4.162

10.  Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.

Authors:  Michael Thomas; Shaymaa S Mousa; Shaker A Mousa
Journal:  Clin Ophthalmol       Date:  2013-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.